The SD GlucoMentor Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips, forearm, upper arm, or palm. The SD GlucoMentor Blood Glucose Monitoring System is intended to be used by a single person and should not be shared. It is intended for self testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid to monitor the effectiveness of diabetes control.

The SD GlucoMentor Blood Glucose Monitoring System should not be used for the diagnosis of or screening for diabetes, or for neonatal use. Alternative site testing should be done only during steady - state times (when glucose is not changing rapidly).

The SD GlucoMentor Test Strips are for use with the SD GlucoMentor Blood Glucose Meter to quantitatively measure glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips, forearm, upper arm, or palm.

The SD GlucoMentor multi Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose (sugar) in fresh capillary whole blood from fingertip, palm, upper arm, or forearm. The SD GlucoMentor multi Blood Glucose Monitoring System is intended for testing outside the body (in vitro diagnostic use) and is intended for multiple-patient use in professional healthcare settings as an aid to monitor the effectiveness of diabetes control program. This system should only be used with auto-disabling, single-use lancing devices. The SD GlucoMentor multi Blood Glucose Monitoring System should not be used for the diagnosis of or screening for diabetes, or for neonatal use. Alternative site testing should be done only during steady - state times (when glucose is not changing rapidly). The SD GlucoMentor multi Blood Glucose Test Strips are for use with the SD GlucoMentor multi Blood Glucose Meter to quantitatively measure glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips, forearm, upper arm, or palm.

Device Description

SD GlucoMentor™ blood glucose system is an Rx/OTC blood glucose monitoring system to be used by professional healthcare personnel or diabetics at home to measure the glucose concentration for aiding diabetes management.

SD GlucoMentor™ blood glucose monitoring system is comprised of the following.

SD GlucoMentor"M blood glucose meter -
SD GlucoMentor™ blood glucose test strip -
-SD Glucose control solution
-SD Glucose check strip

A drop of blood sample from the finger prick works with glucose oxidase and the mediators in the test strip to make a small electric current proportional to the glucose concentration in the blood. The meter reads the current and displays the blood glucose result equivalent to the current.

The system is a battery-operated portable device and stores 500 test results in memory. The user can search the stored results with three presentations of 7, 14 and 30-day averages of test results stored in memory: normal, pre-meal and post-meal state averages. The system can set the beep, hypo warning. date, time, post-meal alarm. The system can also set the pre-meal and post-meal mark. Test results are displayed with mg/dL unit. A check strip allows the meter to check a problem and the control solution allows the meter and test strip to be checked.

AI/ML Overview

The provided text describes the SD GlucoMentor™ Blood Glucose Monitoring System, but it does not contain detailed acceptance criteria or a study proving that the device meets specific performance criteria in the format requested.

The document is a 510(k) Summary, which typically focuses on demonstrating substantial equivalence to a predicate device rather than providing a standalone performance study with detailed acceptance criteria and results.

However, I can extract the information that is present and highlight what is missing based on your request.

Here's a breakdown of the available information and what's not present:

1. Table of Acceptance Criteria and Reported Device Performance

This information is not explicitly provided in the document. The document mentions types of testing performed (e.g., Performance Evaluation, Electromagnetic Compatibility Study (ISO 15197:2003)), but it does not specify the quantitative acceptance criteria (e.g., accuracy percentages, limits of agreement) or the precise reported device performance metrics against those criteria.

2. Sample size used for the test set and the data provenance

The document mentions:

"A system accuracy evaluation (Method Comparison with Predicate Device) for the SD GlucoLink Blood Glucose Monitoring System was performed according to ISO 15197:2003."
"A user performance study was performed to demonstrate that lay consumers could obtain accurate results using the SD GlucoLink Blood Glucose Monitoring System. The study was performed using capillary whole blood from fingertip, palm, forearm, and upper arm sample sites."

However, the specific sample sizes for these studies are not provided.
Data provenance (country of origin, retrospective/prospective) is also not specified. Given SD Biosensor, Inc.'s address in Korea, it's possible the studies were conducted there, but this is not stated. The studies appear to be prospective clinical studies based on the descriptions ("performed using capillary whole blood from...").

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

This information is not provided. For blood glucose monitors, the ground truth is typically established using a reference laboratory method (e.g., YSI analyzer). Certified laboratory personnel would operate such equipment, but they are not "experts" in the sense of clinical reviewers for imaging AI.

4. Adjudication method

This information is not provided. For blood glucose measurements, adjudication methods as described (e.g., 2+1) are not typically applicable. The reference method provides the established true value.

5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

No MRMC comparative effectiveness study was done. This device is a blood glucose monitoring system, which does not involve "human readers" interpreting medical images or data that an AI would assist with in the traditional sense of an MRMC study.

6. If a standalone (i.e. algorithm only without human-in-the loop performance) was done

Yes, the system accuracy evaluation is a standalone performance test of the device. The "user performance study" then tests the device with human-in-the-loop (lay consumers) to ensure they can obtain accurate results, but the primary measurement is algorithmic. However, the standalone performance metrics are not detailed.

7. The type of ground truth used

The ground truth for blood glucose monitoring systems is typically established using a reference laboratory method, such as a hexokinase-based enzymatic method performed on a YSI analyzer or similar highly accurate laboratory instrument. While not explicitly stated as "YSI," the "system accuracy evaluation (Method Comparison with Predicate Device)" implies comparison against a highly accurate reference.

8. The sample size for the training set

This information is not applicable/not provided. Blood glucose monitoring systems typically rely on established electrochemical principles calibrated during manufacturing; they are generally not "trained" on large datasets in the way a machine learning algorithm for image analysis would be.

9. How the ground truth for the training set was established

This information is not applicable/not provided for the reasons mentioned in point 8.

Summary of Missing and Provided Information:

Information Requested	Status in Document
1. Acceptance Criteria Table	NOT PROVIDED (only types of tests mentioned)
2. Test Set Sample Size & Data Provenance	NOT PROVIDED (sample sizes) / Limited (provenance - likely prospective, possibly Korea)
3. Ground Truth Experts & Qualifications	NOT APPLICABLE (ground truth usually from lab reference method, not clinical experts for adjudication)
4. Adjudication Method	NOT APPLICABLE (not relevant for blood glucose measurements)
5. MRMC Comparative Effectiveness Study & Effect Size	NOT APPLICABLE (not an AI-assisted interpretation device)
6. Standalone Performance	Yes, implied by "System accuracy evaluation", but metrics not detailed.
7. Type of Ground Truth	Reference laboratory method (implied, not explicitly named, e.g., YSI)
8. Training Set Sample Size	NOT APPLICABLE (not an ML-trained device)
9. How Training Set Ground Truth Established	NOT APPLICABLE (not an ML-trained device)

This 510(k) summary focuses on demonstrating equivalence to an existing device rather than providing a detailed performance report with specific acceptance criteria and outcome data as might be found in a clinical trial publication.

Summary

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image shows the logo for SD Biosensor, Inc. The logo consists of a stylized graphic to the left, followed by the letters "SD" in bold, and then the words "BIOSENSOR, INC." The text is in a sans-serif font and is all in black.

510(k) Summary

This summary of 510(k) safety and effectiveness information is being submitted in accontance with the regirements of SMPA 1990 and 21 CFR 807.92.

The assigned 510(k) number is: K123517

Date of Summary : September 30, 2013.

1. SUBMITTER'S IDENTIFICATION:

SD Biosensor, Inc.

Address

C-4th &5th Floor Digital Empire Building 980-3, Yeongtong-dong

Yeongtong-gu Suwon-si, Kyonggi-do Korea, 443-813

82-31-300-0418 TEL:

FAX: 82-31-300-0497

Contact Person

Ms. Anis Kim

QA/RA Assistant manager

2. DEVICE NAME:

Proprietary Name	: SD GlucoMentor™
Common Name	: Blood Glucose Monitoring System
Regulation Number	: 21 CFR §862.1345
Classification Name	: Blood Glucose Test System, Over the Counter
Product Code	: NBW
Subsequent Product Code	: CGA / JJX
Regulatory Class	: II

3. PREDICATE DEVICES:

	Predicate Device
(510(k) Number)	K100398
(Device Name)	SmartLink™ Gold

4. DEVICE DESCRIPTION:

SD GlucoMentor™ blood glucose system is an Rx/OTC blood glucose monitoring system to be used

{1}------------------------------------------------

Image /page/1/Picture/0 description: The image shows the logo for SD Biosensor, Inc. The logo consists of a stylized graphic to the left, followed by the letters "SD" in bold, and then the words "SD BIOSENSOR, INC." The text is in a bold, sans-serif font.

by professional healthcare personnel or diabetics at home to measure the glucose concentration for aiding diabetes management.

SD GlucoMentor™ blood glucose monitoring system is comprised of the following.

SD GlucoMentor"M blood glucose meter -
SD GlucoMentor™ blood glucose test strip -
-SD Glucose control solution
-SD Glucose check strip

5. INDICATION FOR USE:

{2}------------------------------------------------

Image /page/2/Picture/0 description: The image shows the logo for SD BIOSENSOR, INC. The logo consists of the letters "SD" in bold, black font, with a stylized graphic to the left of the letters. The words "BIOSENSOR, INC." are written in a smaller, black font to the right of the letters "SD". The logo is simple and professional, and it is likely used to represent the company on its website, marketing materials, and products.

use in professional healthcare settings as an aid to monitor the effectiveness of diabetes control program. This system should only be used with auto-disabling, single-use lancing devices. The SD GlucoMentor multi Blood Glucose Monitoring System should not be used for the diagnosis of or screening for diabetes, or for neonatal use. Alternative site testing should be done only during steady - state times (when glucose is not changing rapidly). The SD GlucoMentor multi Blood Glucose Test Strips are for use with the SD GlucoMentor multi Blood Glucose Meter to quantitatively measure glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips, forearm, upper arm, or palm.

6. COMPARISION TO PREDICATE DEVICE:

The SD GlucoMentor™ blood glucose monitoring system of SD Biosensor, Inc. is substantially equivalent to our SD SmartLink™ GOLD Glucose Monitoring System, K100398. Both the subject and predicate devices are similar in intended use and basic fundamental scientific technology with differences in:

A. SD GlucoMentor™ Meter Appearance, Size, Weight, Color, Codechip, PCB, LCD
B. SD GlucoMentor"M Test strip Printed Film, Size

7. DISCUSSION OF NON-CLINICAL TESTS PERFORMED FOR DETERMINATION OF SUBSTANTIAL EQUIVALENCE ARE AS FOLLOWS:

Based on our risk analysis evaluation results, and, in accordance with the FDA "Draft Guidance for Industry and FDA Staff - Total Product Life Cvcle for Portable Invasive Blood Glucose Monitoring Systems, 10/24/06", outlined performance characteristics, the following testing was conducted to support the modifications found in our subject device:

. Software Verification and Validation Testing
Precision Evaluation
Linearity Testing
. Performance Evaluation
. Equipment Temperature & Humidity Exposure Test
Mechanical Resistance to Vibration-Environmental Testing
. Document TD-8 Testing Temperature Study
. Electromagnetic Compatibility Study (ISO 15197:2003)
. Electrical Safety Study (IEC 61010-1 & IEC 61010-2)

None of the testing demonstrated any design characteristics that violated the requirements of the FDA recognized standards or resulted in any safety hazards. It was our conclusion that testing met all relevant standards requirements.

{3}------------------------------------------------

Image /page/3/Picture/0 description: The image shows the logo for SD Biosensor, Inc. The logo consists of a stylized graphic to the left of the letters "SD", followed by the words "SD BIOSENSOR, INC." The text is in a bold, sans-serif font and is black in color. The logo appears to be for a company in the biosensor industry.

8. DISCUSSION OF CLINICAL TESTS PERFORMED:

Clinical sensitivity and clinical specificity testing is not applicable.

A system accuracy evaluation (Method Comparison with Predicate Device) for the SD GlucoLink Blood Glucose Monitoring System was performed according to ISO 15197:2003.

A user performance study was performed to demonstrate that lay consumers could obtain accurate results using the SD GlucoLink Blood Glucose Monitoring System. The study was performed using capillary whole blood from fingertip, palm, forearm, and upper arm sample sites.

9. CONCLUSION:

Based on documentation supplied with this submission, conclusions drawn from clinical and bench testing of the subject device demonstrates that the subject

The SD GlucoMentor"M blood glucose monitoring system is substantially equivalent to predicated our legally marketed predicate device, Smartlink GOLD (K100398).

{4}------------------------------------------------

Image /page/4/Picture/0 description: The image shows the text "DEPARTMENT OF HEALTH & HUMAN SERVICES" in all caps. The text is in a bold, serif font. The text is centered horizontally and vertically in the image.

Image /page/4/Picture/1 description: The image is a black and white logo for the Department of Health & Human Services - USA. The logo consists of a circular border with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the top half of the circle. Inside the circle is a stylized image of an eagle or bird-like figure with three curved lines representing its body and wings.

Public Health Service

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G6()9 Silver Spring, MD 20993-0002

February 6, 2014

SD BIOSENSOR JIGAR SHAH JIGAR MDI CONSULTANTS 55 NORTHERN BLVD GREAT NECK NY 11021

Re: K123517

Trade/Device Name: GlucoMentor Blood Glucose Monitoring System, GlucoMentor Multi Blood Glucose Monitoring System Regulation Number: 21 CFR 862.1345 Regulation Name: Glucose test system Regulatory Class: II Product Code: NBW, CGA, JJX Dated: January 10, 2014 Received: January 13, 2014

Dear Mr. Shah:

This letter corrects our substantially equivalent letter of January 17, 2014.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act

{5}------------------------------------------------

Page 2 - [Jigar Shar]

or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part Parts 801 and 809 ), please contact the Division of Small Manufacturers. International and Consumer Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.

Sincerely vours.

Katherine Serrano -S

For:

Courtney H. Lias, Ph.D. Director Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health

Enclosure

{6}------------------------------------------------

Indications for Use Statement

510(k) Number

K123517

Device Name

SD GlucoMentor"M multi blood glucose monitoring system

INDICATIONS FOR USE

The SD GlucoMentor multi Blood Glucose Monitoring System should not be used for the diagnosis of or screening for diabetes, or for neonatal use. Alternative site testing should be done only during steady state times (when glucose is not changing rapidly).

The SD GlucoMentor multi Blood Glucose Test Strips are for use with the SD GlucoMentor multi Blood Glucose Meter to quantitatively measure glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips, forearm, upper arm, or palm.

Prescription Use X AND/OR (Part 21 CFR 801 Subpart D)

Over-The-Counter Use _ X (Part 21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Device (OIVD) Katherine Serrano=S 2014.02.06 11:49:10 05 00

Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety

K123517 210(k)

Regulation Number and Section

§ 862.1345 Glucose test system.

(a)
Identification. A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.(b)
Classification. Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.